Research and Markets: World Adenocarcinoma of the Gastroesophageal Junction Pipeline Review, H2 2015 - 28 Companies & 32 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/mldx7x/adenocarcinoma_of) has announced the addition of the "Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • AB Science SA
  • Amgen Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cerulean Pharma, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ganymed Pharmaceuticals AG
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Imugene Limited
  • Johnson & Johnson
  • Mebiopharm Co., Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Otsuka Holdings Co., Ltd.
  • Panacea Biotec Limited
  • Sanofi

Drug Profiles

  • (tipiracil hydrochloride + trifluridine)
  • alpelisib
  • AMG-337
  • avelumab
  • AZD-4547
  • BI-853520
  • cabazitaxel
  • CRLX-101
  • DS-8201a
  • durvalumab + tremelimumab
  • emibetuzumab
  • erismodegib
  • GS-5745
  • Her-VAXX
  • IMAB-362
  • indusatumab vedotin
  • ipatasertib
  • ipilimumab
  • JNJ-42756493
  • masitinib
  • MBP-426
  • napabucasin
  • panitumumab
  • PDR-001
  • pembrolizumab
  • pertuzumab
  • ramucirumab
  • SAR-408701
  • solitomab
  • tivantinib
  • trastuzumab biosimilar
  • trastuzumab emtansine

For more information visit http://www.researchandmarkets.com/research/mldx7x/adenocarcinoma_of

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology